Maryland’s Bioscience Environment: 2010 – Facts and Figures
General Profile –
- Maryland is home to more than 500 core bioscience companies, representing approximately 8% of the U.S. industry. This is the 2ndlargest cluster (per capita) in the U.S. and 4th overall in “core biotechnology” companies (Ernst and Young, 2006-2008).
- Approximately one-half of Maryland’s bioscience industry is engaged in therapeutic development, primarily biotherapeutics as opposed to small chemical molecules. Another 25 % provide supporting research services (“CROs”). The rest are creating gene-based diagnostics, integrating biologics and nanotechnology into medical devices, and developing innovative R&D technology platforms.
- There are approximately 45 Maryland companies conducting more than150 clinical trials with preclinical pipeline development programs for novel biotherapeutics. Clinical focus strengths include oncology, CNS, cardiovascular, and infectious disease with a strong vaccine development expertise.
- The State of Maryland has invested more than $700 million in infrastructure (research parks, institutes, etc.), programs (Maryland Venture Fund, Biotechnology Investor Tax Credit, Nanobiotechnology) and directly to bioscience companies over the past 20 years.
- In May 2009, Governor Martin O’Malley unveiled BioMaryland 2020 – the State Strategic Plan for Life Sciences that calls for an investment of over$1.3 billion in ten years and a product of 1-1/2 years of effort by theMaryland Life Sciences Advisory Board (LSAB) and 100 dedicated members of Maryland’s bioscience community.
- Maryland has the third largest state Stem Cell Research Fund that has committed funding of more than $50 million for peer reviewed research grants to date. Total fund commitment is $71.4 million (FY 2007 – 2010).
- The Maryland Biotechnology Investor Tax Credit, now in its sixth year of funding, has stimulated 5 years of investments of just over $64 million in 53 entrepreneurial bioscience enterprises.
Corporate Activity –
- Maryland bioscience companies accounted for the most Initial Public Offerings or “IPOs” (5) in the Mid-Atlantic in recent years (2004-2006) including more than $500 million in financing during that period.
- Maryland venture capital activity in bioscience (biotechnology, medical devices and equipment) reached $286 million in 43 deals in 2006.
- MedImmune, which was the 6th largest biotechnology company globally, was acquired in 2007 by Astra Zeneca (UK/Sweden) for $15 billion.
- Teva Pharmaceutical (Israel) acquired CoGenesys, a Human Genome Sciences spin-out company, for $400 million in 2008.
- Qiagen NV (Germany), which established its U.S. headquarters in MD in 2001, acquired Digene (an original MD biotechnology company) for $1.6 billion in 2008. Note: In all cases, the parent organizations remained dedicated to expanding operations in MD.
Recent Maryland Rankings –
- Maryland was recently ranked 2nd nationally in Milken’s Institute State Technology and Science Index, moving from 4th last year to out-pace California and behind only Massachusetts. (Milken, 2008)
- Maryland has been ranked 2nd globally for initiatives aimed at drawing and retaining biotech companies (FiierceBiotech, 2006)
- Maryland has been ranked 2nd highest in the number of biotech start-ups in the U.S. in 2004 (BioMiner, 2005)
Education and Skilled Workforce –
- Maryland ranked 1st in Milken’s 2008 Human Capital Investment Index, a measure of the state’s human capital and how adequately the state is prepared to sustain employment in science and technology fields. (Milken, 2008)
- Maryland ranks 2nd among the states in the total number of doctoral scientists and engineers as a percentage of total employment(2007)
- MD ranks 2nd in the percentage of professional and technical workers (25.4%). Just over 35% of the workforce has a bachelors (BA/BS) degree or higher.
- In addition, MD is also ranked 1st in Biological Sciences, Health Sciences, and Mathematics doctorates (per capita).
- Maryland’s higher education institutions have approximately 1/3 of their enrollment (~95,000 students) in degree programs that directly feed the bioscience industry.
R & D Intensity –
- Maryland ranks 2nd among the states in research and development intensity, which is the ratio of R&D expenditures to gross domestic product (GDP) by state. Source: NSF, 2004
- Maryland’s universities receive more than $1.7 billion in NIH research grants and contract awards, and conduct more than $2 billion in R&D.
- Johns Hopkins University ranks first among U.S. colleges and universities in total National Institutes of Health awards, including grants and contracts for research, development, training and fellowships: $607 million. Source: NIH, 2005
- Maryland ranks first in the nation in National Institutes of Health research and development contract awards ($757 million). Source: NIH, 2005
- Johns Hopkins University ranks first among academic institutions in the nation in research and development expenditures, totaling $1.5 billion in FY 2006. The university also ranks first in federally funded research: $1.31 billion. Source: NSF, 2005
- Maryland ranks second nationally in federal obligations for research and development ($12.2 billion). On a per capita basis, Maryland ranks firstamong the states in federal R&D obligations.
Source: NSF 2005, and State Science and Technology Institute.
Economic Impact to Maryland –
- The life sciences sector accounted for 1/3 of all job gains during 2002 to 2010
- Over 1,700 private sector establishments are directly involved in life sciences work – 5th highest concentration in the US.
- Life sciences directly accounts for 71,600 jobs – 3% of all jobs in Maryland.
– 33,600 Private
– 29,800 Federal
– 8,250 Academic
- Maryland life sciences direct salaries total $6.5 billion.
- Average life sciences salary across sectors is $91,100, 76% higher than the state’s average.
- 6% of Maryland’s GDP – $17.6 billion – is generated by the life sciences.
- Including direct, indirect and induced jobs, the life sciences support 160,030 jobs — 6.5% of the state’s total — and equivalent to $9.6 billionin salaries.
- Life sciences activity support nearly $500 million in annual income and sales taxes.
